Regulatory approval

Published by the Health Service Executive. Approved

Neoadjuvant treatment of adult patients with HER2-positive locally advanced, inflammatory or early breast cancer at high risk of recurrence.

This is written in the approval document.

Reimbursement

Hybrid

Pertuzumab - ODMS; Trastuzumab, Carboplatin, Docetaxel - Hospital

Citation

DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) Therapy, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6598/722_v2_TCHP.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab